Point2 Completes $136M Series B Funding with Arm, LB Investment, and Maverick Silicon August 10, 2026 New Funding Further Solidifies Point2’s e‑Tube Technology Platform as the Foundation for Next-Generation AI Data-Center Interconnect
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer August 10, 2026 Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management
The World’s Largest AI Companies Built Deployment Arms This Year. Harbor Built One for Law August 10, 2026 Harbor Deploy is the first AI deployment offering built exclusively for law firms and corporate legal departments, bringing the embedded-engineering model now reshaping enterprise AI to the industry where confidentiality, professional judgment, and duty to the client are non-negotiable.
AT&T-Led Neutral-Host Network Powers New Connectivity Experience at Davis Wade Stadium August 10, 2026 AT&T customers at Mississippi State University’s Davis Wade Stadium in Starkville are getting a boost in wireless connectivity following the deployment of a new AT&T-led distributed antenna system, or DAS, powered by Airspan’s MobileAccess 6000 Digital platform. Led and owned by AT&T as a neutral-host network, the new DAS is designed to deliver high-capacity, multi-operator [...]
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results August 10, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders Presented follow-up data from the Phase 1 SANRECO trial [...]
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera August 9, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT. Investor Webcast & Conference Call [...]
Targa Newfoundland Unveils Full Sponsor Ecosystem, Announces Lives Showcase at IBC 2026 Amsterdam August 7, 2026 Dejero, ADLINK Technology, Eutelsat and Intel among the sponsors powering the first-ever livestream of North America's only tarmac rally, with a live demonstration at IBC and a video message from professional racing driver Randy Pobst.
Algoma Central Corporation Reports Financial Results for the 2026 Second Quarter August 7, 2026 Strategic acquisitions, expanded credit facilities, and strong segment performance position Algoma for continued growth.
Battery Ventures Promotes Brandon Gleklen to Partner August 7, 2026 Gleklen, who invests in AI-application companies, joins new principal Jason Mendel and eight other investors globally promoted to new roles